501 related articles for article (PubMed ID: 36697706)
21. Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma.
Merters J; Lamarca A
J Hepatol; 2023 Mar; 78(3):652-657. PubMed ID: 36400328
[TBL] [Abstract][Full Text] [Related]
22. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications.
Kankeu Fonkoua LA; Serrano Uson Junior PL; Mody K; Mahipal A; Borad MJ; Roberts LR
Expert Opin Ther Targets; 2022 Jan; 26(1):79-92. PubMed ID: 35034558
[TBL] [Abstract][Full Text] [Related]
23. Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies.
Yu X; Zhu L; Wang T; Chen J
Front Immunol; 2023; 14():1037945. PubMed ID: 37138880
[TBL] [Abstract][Full Text] [Related]
24. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.
Louis C; Edeline J; Coulouarn C
Expert Opin Ther Targets; 2021 Feb; 25(2):153-162. PubMed ID: 33502260
[No Abstract] [Full Text] [Related]
25. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
[TBL] [Abstract][Full Text] [Related]
26. Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part II: Treatment.
Cholangiocarcinoma Working Group
Dig Liver Dis; 2020 Dec; 52(12):1430-1442. PubMed ID: 32952071
[TBL] [Abstract][Full Text] [Related]
27. Updates in the use of targeted therapies for the treatment of cholangiocarcinoma.
Lodl E; Ramnaraign B; Sahin I; Wheeler S
J Oncol Pharm Pract; 2023 Jul; 29(5):1206-1217. PubMed ID: 37097888
[TBL] [Abstract][Full Text] [Related]
28. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
Ross JS; Wang K; Gay L; Al-Rohil R; Rand JV; Jones DM; Lee HJ; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Morosini D; Hawryluk M; Catenacci DV; Miller VA; Churi C; Ali S; Stephens PJ
Oncologist; 2014 Mar; 19(3):235-42. PubMed ID: 24563076
[TBL] [Abstract][Full Text] [Related]
29. Molecular Pathogenesis and Current Therapy in Intrahepatic Cholangiocarcinoma.
Høgdall D; O'Rourke CJ; Taranta A; Oliveira DV; Andersen JB
Dig Dis; 2016; 34(4):440-51. PubMed ID: 27170400
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies.
Argemi J; Ponz-Sarvise M; Sangro B
Adv Cancer Res; 2022; 156():367-413. PubMed ID: 35961706
[TBL] [Abstract][Full Text] [Related]
31. Unveiling the immunogenomic landscape of cholangiocarcinoma: Identifying new prognostic markers and therapeutic targets based on CCL5 expression.
Wang J; Xiang D; Dai Z; Zhu J; Du Y; Fu G; Chu X
J Gene Med; 2024 Jan; 26(1):e3630. PubMed ID: 37985959
[TBL] [Abstract][Full Text] [Related]
32. The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma.
Chiang NJ; Hou YC; Tan KT; Tsai HW; Lin YJ; Yeh YC; Chen LT; Hou YF; Chen MH; Shan YS
Hepatol Int; 2022 Oct; 16(5):1137-1149. PubMed ID: 35780451
[TBL] [Abstract][Full Text] [Related]
33. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
[TBL] [Abstract][Full Text] [Related]
34. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances.
Li D; Lin S; Hong J; Ho M
Adv Cancer Res; 2022; 156():415-449. PubMed ID: 35961708
[TBL] [Abstract][Full Text] [Related]
36. Cholangiocellular Carcinoma.
Vogel A; Saborowski A
Digestion; 2017; 95(3):181-185. PubMed ID: 28288474
[TBL] [Abstract][Full Text] [Related]
37. Immunobiology of cholangiocarcinoma.
Tomlinson JL; Valle JW; Ilyas SI
J Hepatol; 2023 Sep; 79(3):867-875. PubMed ID: 37201670
[TBL] [Abstract][Full Text] [Related]
38. A review of the clinical diagnosis and therapy of cholangiocarcinoma.
Yao D; Kunam VK; Li X
J Int Med Res; 2014 Feb; 42(1):3-16. PubMed ID: 24366497
[TBL] [Abstract][Full Text] [Related]
39. The focus clinical research in intrahepatic cholangiocarcinoma.
Song Y; Cai M; Li Y; Liu S
Eur J Med Res; 2022 Jul; 27(1):116. PubMed ID: 35820926
[TBL] [Abstract][Full Text] [Related]
40. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma.
Li F; Peiris MN; Donoghue DJ
Cytokine Growth Factor Rev; 2020 Apr; 52():56-67. PubMed ID: 31899106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]